University of California Irvine researchers developed glycan-dependent T cell recruiters (GlyTRs), a novel class of biologics that employ velcro-like sugar-binding technology to selectively engage T cells at cancer-associated glycans. This design achieves potent cytotoxicity across multiple solid tumor types without damaging normal cells expressing low antigen levels, overcoming limitations of current bispecific antibodies and CAR T-cell therapies. Preclinical models confirmed safety and efficacy in breast, colon, lung, pancreatic, ovarian, and prostate cancers, signaling a potential universal immunotherapy platform.